Provided by Tiger Trade Technology Pte. Ltd.

Stereotaxis Inc

1.42
-0.0200-1.39%
Post-market: 1.440.0200+1.41%19:59 EDT
Volume:360.85K
Turnover:518.54K
Market Cap:142.29M
PE:-5.80
High:1.47
Open:1.46
Low:1.40
Close:1.44
52wk High:3.59
52wk Low:1.24
Shares:100.20M
Float Shares:71.37M
Volume Ratio:0.54
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2448
EPS(LYR):-0.2519
ROE:-184.27%
ROA:-25.38%
PB:11.62
PE(LYR):-5.64

Loading ...

Lake Street Reaffirms Their Buy Rating on Stereotaxis (STXS)

TIPRANKS
·
Aug 12

Stereotaxis Q2 Revenue Misses Estimates, Dragged by System Decline

Reuters
·
Aug 12

Stereotaxis Catat Rugi Bersih Q2 FY26 Melebar Ke USD 4,5 Juta; Revenue Turun 12,82% Jadi USD 7,7 Juta

Reuters
·
Aug 12

Stereotaxis Q2 Revenue USD 7.67 Million Vs. IBES Estimate USD 8.35 Million

Reuters
·
Aug 12

Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate

Benzinga Earnings
·
Aug 12

Stereotaxis Q2 Recurring Revenue USD 6.2 Million

THOMSON REUTERS
·
Aug 12

Goldman Sachs: AI's Next Main Line Shifts From Computing Power To Humanoid Robots

Analyst Calls
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Aug 11

Mobia Medical Appoints Myriam Curet, M.d., to Its Board of Directors

THOMSON REUTERS
·
Aug 04

Stereotaxis to Report Q2 2026 Results After U.S. Market Close

Reuters
·
Jul 21

Stereotaxis Files Resale Registration for Up to 108.9 Million Shares

MT Newswires Live
·
Jul 16

Stereotaxis - Files for Resale of 108.87 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jul 16

Stereotaxis files to sell 19.45M shares of common stock for holders

TIPRANKS
·
Jul 16

Stereotaxis Completes Acquisition of Robocath

THOMSON REUTERS
·
Jul 09

Stereotaxis shareholders approve Ernst & Young as 2026 auditor at annual meeting

Reuters
·
May 16

Stereotaxis (STXS) Q1 2026 Loss Near US$6 Million Tests Bullish Margin Narrative

Simply Wall St.
·
May 14

Stereotaxis Price Target Cut to $3.50/Share From $4.00 by Piper Sandler

Dow Jones
·
May 13

Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Neurogene (NGNE) and Stereotaxis (STXS)

TIPRANKS
·
May 13

Stereotaxis price target lowered to $3.50 from $4 at Piper Sandler

TIPRANKS
·
May 13